Pricing Log in Create free account

Mineralys Therapeutics, Inc. (MLYS) vs Novavax, Inc. (NVAX)

Mineralys Therapeutics, Inc. and Novavax, Inc. are both Biotechnology companies. Mineralys Therapeutics, Inc. and Novavax, Inc. are of similar size ($1.9B and $1.8B). Mineralys Therapeutics, Inc. has the higher net margin (0.00% vs −59.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Novavax, Inc. leads on 7 and Mineralys Therapeutics, Inc. on 4.

Valuation

Metric MLYS NVAX Biotechnology median
P/E n/m n/m 8.58
P/S n/m 3.98 10.29
P/B 3.28 n/m 2.29
Price to free cash flow n/m n/m 21.93
EV/EBITDA n/m n/m 0.67
EV/Sales n/m 2.95 9.89
Earnings yield (19.86%) (15.20%) (31.56%)
Free cash flow yield (7.68%) (2.68%) (23.42%)

Profitability

Metric MLYS NVAX Biotechnology median
Gross margin — 78.60% 65.77%
Operating margin 0.00% (56.58%) 0.00%
Net margin 0.00% (59.87%) 0.00%
Free cash flow margin 0.00% (10.20%) 0.00%
Return on equity (80.88%) 323.66% (54.09%)
Return on assets (69.67%) (21.62%) (47.78%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MLYS NVAX Biotechnology median
Revenue growth (TTM) — (61.64%) 5.83%
EPS growth (last fiscal year) 37.43% 309.76% 29.36%
Revenue growth, 5-year CAGR — 18.76% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MLYS NVAX Biotechnology median
Debt to equity 0.18 (1.54) 0.00
Current ratio 34.46 2.33 4.80
Net debt to EBITDA 3.85 (1.04) 0.97

Dividend

Metric MLYS NVAX Biotechnology median
Dividend yield — — 0.44%
Payout ratio — — —

Size

Metric MLYS NVAX Biotechnology median
Market cap 1.87b 1.82b 153.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack